The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Paxlovid (nirmatrelvir + ritonavir)…. read more.
NICE (UK) Nirmatrelvir plus ritonavir is recommended as an option for treating COVID‑19 in adults, only if they: i) do not need supplemental oxygen for COVID‑19 and, ii)… read more.
NICE (UK): Molnupiravir is recommended as an option for treating mild to moderate COVID‑19 in adults who have a positive SARS‑CoV‑2 test, only if: i) they have 1… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Veklury. The CHMP adopted… read more.
Vir Biotechnology is cutting one-quarter of its workforce in a move away from infectious disease research. The company, which rose to prominence with its coronavirus antibody work in… read more.
Moderna, Inc. announced that it has submitted an application to the FDA for review of its Spikevax 2024-2025 formula, targeting the SARS-CoV-2 variant JN.1. “For four years, Moderna… read more.
Shionogi & Co., Ltd. announced that its pivotal, double-blind, randomized, placebo-controlled global Phase III study (SCORPIO-HR) did not meet its primary endpoint of a statistically significant reduction in… read more.
Junshi Biosciences has revealed the final results for its Covid-19 pill VV 116 (mindeudesivir hydrobromide), indicating its efficacy. The data, which was published in The Lancet Infectious Diseases… read more.
China’s medical products regulator has given conditional approval for Pfizer’s COVID-19 drug Paxlovid, making it the first oral pill specifically developed to treat the disease cleared in the… read more.
Moderna, Inc., announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna’s mRNA COVID-19 vaccine, Spikevax, in a 50 µg… read more.
Effective 1 January 2022 Pharmaceutical companies can now seek accelerated drug approvals in the UK using the newly launched Innovative Licensing and Access Pathway (ILAP). The new approval… read more.
Johnson & Johnson announced preliminary results from an independent study, including a subset of participants from the Janssen-sponsored COV2008 study, conducted by Dan Barouch, M.D., Ph.D., et al…. read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
